Lapatinib ditosylate GlaxoSmithKline

IDrugs

Volumn 6, Issue 9, 2003, Pages 886-893

  Kim, Tracey E ^a   Murren, John R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GROWTH FACTOR RECEPTOR; GW 20168; IRINOTECAN; LAPATINIB; OXALIPLATIN; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IC 50; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NONHUMAN; REVIEW; SOLID TUMOR; STEADY STATE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; FURANS; HUMANS; NEOPLASMS; QUINAZOLINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0141719490     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. 210623 Phase II study of weekly intravenous recombinant humanized anti-p185 Her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PR et al. J Clin Oncol 1996 14 3 737-744
2. 272316 Inhibitors of tyrosine kinase. Klohs WD, Fry DW, Kraker AJ Curr Opin Oncol 1997 9 6 562-568 Useful review on TK inhibitors selective for EGFR.
3. 286424 Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Strawn LM, Shawver LK Expert Opin Investig Drugs 1998 7 4 553-573
4. 303414 Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Science 1987 235 4785 177-182
5. 330780 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A Science 1989 244 4905 707-712
6. 352971 The epidermal growth factor receptor and its inhibition in cancer therapy. Woodburn JR Pharmacol Ther 1999 82 2 241-250
7. 352972 Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy progression from reversible to irreversible inhibitors. Fry DW Pharmacol Ther 1999 82 2 207-218
8. 365612 Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA Semin Oncol 1999 62 4 Suppl 12 60-70
9. 365628 Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J Cancer Res 1998 58 13 2825-2831
10. 390936 Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP J Pharmacol Exp Ther 1999 291 2 739-748
11. 403973 GW2016, a dual inhibitor of ErbB-2 and EGFR tyrosine kinases: Effects on receptor tyrosine autophosphorylation, downstream signaling intermediaries, and in vivo anti-tumor activity. Xia W, Mullin R, Keith B, Rusnak D, Alligood K, Owens G, Murray D, Crosby R, Finlay C, Gilmer T, Lackey K et al. Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 3635
12. 404256 Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Ye D, Mendelsohn J, Fan Z Oncogene 1999 18 3 731-738
13. 404776 The discovery of a new anti-cancer agent GW2016: A potent, dual EGFR/ErB-2 tyrosine kinase inhibitor. Lackey KE, Affleck K, Allen P, Alligood KJ, Cai Z, Carter MC, Cockerill S, Crosby RM, Dickerson S, Frye SV, Gaul M Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4582
14. 405059 Antitumor activity of GW2016 in the EGFR positive human head and neck cancer xenograft, HN5. Mullin RJ, Alligood KJ, Allen PP, Crosby RM, Keith BR, Lackey K, Gilmer TM, Griffin RJ, Murray DM, Tadepalli SM Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4579
15. 405293 Anti-tumor activity of GW2016 in the ErbB-2 positive human breast cancer xenograft, BT474. Keith BR, Allen PP, Alligood KJ, Crosby RM, Lackey K, Gilmer TM, Mullin RJ Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4308
16. 405294 The effects of the novel EGFR/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and transformed cell lines. Rusnak DW, Affleck K, Gilmer TM, Jowett A, Lackey K, Spector N, Xia W Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4309
17. 405307 Optimizing EGFR and ErbB-2 tyrosine kinase inhibition: Structure activity relationship studies around the core 6-furanyl quinazoline template. Glennon K, Affleck K, Cai Z, Cockerill SG, Dickerson S, Gauthier CA, Griffin RJ, Keith BR, Knight WB, Lackey KE, Mullin RJ et al. Proc Annu Meet Am Assoc Cancer Res 2001 42 Abs 4310
18. 447534 Therapeutic advantage of a dual tyrosine kinase inhibitor (GW2016) in combination with chemotherapy drugs or trastuzumab against human breast cancer cells with HER2 overexpression. Konecny GE, Venkatesan N, Beryt M, Finn R, Slamon DJ, Lackey K, Rusnak DW, Pegram M Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 4974
19. 448963 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland JB, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L N Engl J Med 2001 344 11 783-792
20. 451835 A phase I pharmacokinetic/pharmacodynamic study evaluating multiple doses of oral GW572016 in healthy subjects. Adams VR, Bence AK, Anderson EB, Halepota MA, Smith DA, Koch KM, Bowen CJ, Mangum SG, Spector NL, Davis GA, Doukas MA, DeSimone PA Proc Am Soc Clin Oncol 2002 21 Abs 374
21. 451844 A phase I study to investigate the safety, tolerability, and pharmacokinetics of single oral escalating doses of GW572016 in healthy volunteers. DeSimone PA, Bence AK, Anderson EB, Halepota MA, Smith DA, Koch KM, Stead AG, Mangum SG, Spector NL, Davis GA, Doukas MA, Adams VR Proc Am Soc Clin Oncol 2002 21 Abs 375
22. 454603 Effects of an aldose reductase inhibitor, fidarestat, on the increase of oxidative stress and VEGF production in human retinal pigment epithelial cells exposed to high glucose. Taniko K, Mukae N, Hirooka H, Kato N, Jomori T Diabetes 2002 51 2 Abs 836P
23. 454703 The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Rusnak DW, Lackey K, Affleck K, Wood E, Alligood KJ, Rhodes N, Keith BR, Murray DM, Glennon K, Knight WB, Mullin RJ et al. Mol Cancer Ther 2001 1 2 85-94
24. 454900 Cell signaling by receptor tyrosine kinases. Schlessinger J Cell 2000 103 2 211-225
25. 454996 ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Graus-Porta D, Beerli RR, Daly JM, Hynes NE EMBO J 1997 16 7 1647-1655
26. 455014 Epidermal growth factor-related peptides and their receptors in human malignancies. Salomon DS, Brandt R, Ciardiello F, Normanno N Crit Rev Oncol Hematol 1995 19 3 183-232
27. 455345 Untangling the ErbB signalling network. Yarden Y, Sliwkowski MX Nat Rev Mol Cell Biol 2001 2 2 127-137
28. 460591 Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-α. Wikstrand CJ, Bigner DD J Natl Cancer Inst 1998 90 11 799-801
29. 460593 Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Chen X, Yeung TK, Wang Z Biochem Biophys Res Commun 2000 277 3 757-763
30. 460597 Signal transduction by allosteric receptor oligomerization. Schlessinger J Trends Biochem Sci 1988 13 11 443-447
31. 467734 Product development pipeline - October 2002. GlaxoSmithKline Plc Company Publication 2002 October 23
32. 471987 A phase III clinical trial of ZD1839 in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT 1). Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf M, Rennie P, Ochs J, Averbuch S, Faudi A Proc Eur Med Soc Oncol 2002 2 Abs 4
33. 472744 American Association of Pharmaceutical Scientists 2002 Annual Meeting and Exposition (Part III) - Toronto, Canada. Koushik K, Kompella U IDDB Meeting Report 2002 November 10-14
34. 474696 Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/ErbB2 and downstream Erk1/2 and AKT pathways. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL Oncogene 2002 21 41 6255-6263
35. 478510 Product development pipeline - December 2002. GlaxoSmithKline Plc Company Publication 2003 February 12
36. 483258 Potential benefits of the irreversible pan-ErbB inhibitor, CI-1033, in the treatment of breast cancer. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW Semin Oncol 2002 29 3 Suppl 11 11-21
37. 489651 Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. Cohen S, Carpenter G, King L J Biol Chem 1980 255 10 4834-4842
38. 489652 The neu oncogene encodes an epidermal growth factor receptor-related protein. Bargmann CI, Hung MC, Weinberg RA Nature 1986 319 6050 226-230
39. 489653 Isolation and characterization of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors. Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA Proc Natl Acad Sci USA 1989 86 23 9193-9197
40. 489656 Ligand-specific activation of HER4/p180ErbB4, a fourth member of the epidermal growth factor receptor family. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M Proc Natl Acad Sci USA 1993 90 5 1746-1750
41. 489661 A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y Mol Cell Biol 1996 16 10 5276-5287
42. 489662 Insect cell-expressed p180ErbB3 possesses an impaired tyrosine kinase activity. Guy PM, Platko JV, Cantley LC, Cerione RA, Caraway KL Proc Natl Acad Sci USA 1994 91 17 8132-8136
43. 489663 Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Kokai Y, Myers JN, Wada T, Brown VI, LeVea CM, Davis JG, Dobashi K, Greene MI Cell 1989 58 2 287-292
44. 489664 Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy. Dougall WC, Qian X, Greene MI J Cell Biochem 1993 53 1 61-73
45. 489670 The ErbB signaling network: Receptor heterodimerization in development and cancer. Olayioye MA, Neve RM, Lane HA, Hynes NE EMBO J 2000 19 13 3159-3167
46. 489672 Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS Ann Oncol 1997 8 12 1197-1206
47. 489673 Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Bargmann CI, Hung MC, Weinberg RA Cell 1986 45 5 649-657
48. 489675 Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the ErbB-2 gene. Segatto O, King CR, Pierce JH, Di Fiore PP, Aaronson SA Mol Cell Biol 1988 8 12 5570-5574
49. 489676 A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI Nature 1989 339 6221 230-231
50. 489680 c-ErbB2 amplification and overexpression in human tumors. Lofts FJ, Gullick WJ Cancer Treat Res 1992 61 161-179
51. 489682 Overexpression of HER2/neu in solid tumours: An immunohistochemical survey. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Slikowski MX, Hillan KJ Histopathology 2001 38 2 96-104
52. 489690 Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke Pearson DL, Bast RC Obstet Gynecol 1990 76 3 Pt 1 381-387
53. 489693 Epidermal growth factor receptor, c-ErbB-2 and p53 overexpressions in epithelial hyperplastic lesions of the larynx. Gale N, Zidar N, Kambic V, Poljak M, Cor A Acta Otolaryngol Suppl 1997 527 105-110
54. 489698 Expression of epidermal growth factor receptor family proteins (EGFR, c-ErbB-2 and c-ErbB-3) in gastric cancer and chronic gastritis. Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, Wojnar A Anticancer Res 1998 18 4A 2727-2732
55. 489702 Expression of the tyrosine kinase activity growth factor receptors (EGFR, Erb B2, Erb B3) in colorectal adenocarcinomas and adenomas. Porebska I, Harlozinska A, Bojarowski T Tumor Biol 2000 21 2 105-115
56. 489708 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ J Clin Oncol 1999 17 9 2639-2648
57. 489716 Therapeutic application of anti-growth factor receptor antibodies. Fan Z, Mendelsohn J Curr Opin Oncol 1998 10 1 67-73
58. 489741 Perspectives on anti-HER monoclonal antibodies. Ransom M, Sliwkowski MX Oncology 2002 63 Suppl 1 17-24
59. 489742 Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C J Steroid Biochem 1989 34 1-6 123-131
60. 489743 Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, Danenberg PV Clin Cancer Res 2001 7 7 1850-1855
61. 489744 Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J Cancer Res 1997 57 15 3272-3280
62. 489745 Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. Qian X, LeVea CM, Freeman JK, Dougall WC, Greene MI Proc Natl Acad Sci USA 1994 91 4 1500-1504
63. 489845 Active signaling by Neu in transgenic mice. DiGiovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, Stern DF Oncogene 1998 17 14 1877-1884
64. 489848 Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism. Huang G, Chantry A, Epstein RJ J Cell Biochem 1999 74 1 23-30
65. 489850 Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Egeblad M, Mortensen OH, Jaattela M Int J Cancer 2001 94 2 185-191
66. 489851 ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. Worthylake R, Opresko LK, Wiley HS J Biol Chem 1999 274 13 8865-8874
67. 489860 Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S Ann Oncol 2002 13 1 65-72
68. 492986 A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU in combination with irinotecan and/or oxaliplatin. Belanger M, Jones CM, Germond C, Berger MS Proc Am Soc Clin Oncol 2002 22 Abs 978
69. 492991 A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Kaplan EH, Jones CM, Berger MS Proc Am Soc Clin Oncol 2003 22 Abs 981
70. 493026 A phase I study of GW572016 in patients with solid tumors. Burris HA, Taylor C, Jones S, Pandite L, Smith DA, Versola M, Stead A, Whitehead B, Spector N, Wilding G Proc Am Soc Clin Oncol 2003 22 Abs 994
71. 493275 Phase I and pharmacokinetic (PK) study of oral GW572016, a potent reversible dual inhibitor of both ErbB1 and ErbB2 tyrosine kinase (TK), administered in combination with capecitabine. De Bono JS, Schwartz G, Monroe P, Beeram M, Hammond L, Smith D, Loftiss J, Stead A, Pandite L, Rowinsky EK Proc Am Soc Clin Oncol 2003 22 Abs 901
72. 493292 Safety, clinical efficacy, and biologic assessments from EGF100004: A randomized phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or ErbB2. Spector N, Raefsky E, Hurwitz H, Hensing T, Dowalti A, Dees C, O'Neill B, Smith DA, Mangum S, Burris HA Proc Am Soc Clin Oncol 2003 22 Abs 772
73. 493445 ZD1839 ('Iressa') in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT 2). Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, Wolf M, Helton A, Averbuch S, Grous J Ann Oncol 2002 13 Suppl 5 Abs 4680